Want to see TSE:DHB full AI Analyst Report?
DHB Stock Chart & Stats
C$0.10
-C$0.01(-10.00%)
At close: 4:00 PM EDT
C$0.10
-C$0.01(-10.00%)
Day’s Range― - ―
52-Week RangeC$0.09 - C$0.37
Previous CloseN/A
Volume6.06K
Average Volume (3M)26.13K
Market Cap
C$3.44M
Enterprise ValueC$2.98M
Total Cash (Recent Filing)C$2.64M
Total Debt (Recent Filing)C$2.33M
Price to Earnings (P/E)―
Beta1.87
Next Earnings
Oct 23, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding31,261,782
10 Day Avg. Volume58,945
30 Day Avg. Volume26,134
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)1.30
Price to Sales (P/S)0.41
P/FCF Ratio-7.30
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$0.53Price Target Upside430.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.01
Revenue Forecast (FY)C$14.12M
Bulls Say, Bears Say
Bulls Say
High Gross Margins (~45.5% TTM)A ~45.5% gross margin provides durable product-level profitability potential for OTC goods. High gross margins give room to cover fixed costs and marketing, enabling operating leverage as sales stabilize or grow, and supporting eventual path to consistent operating profitability.
Focused OTC Consumer-health Business ModelA concentrated OTC wellness model targets stable, repeat-purchase categories and broad retail/distribution channels. Structural demand for non-prescription health products tends to be resilient, helping revenue predictability and supporting long-term shelf presence and distributor relationships.
Operating Loss Trajectory Has Improved Versus Prior Extreme LossesEvidence of materially improved losses versus earlier years suggests management has reduced burn and improved cost structure. This trend increases the probability of reaching break-even within months if execution continues, lowering multi-year execution risk relative to prior periods.
Bears Say
Declining Revenue (-14.1% TTM)A material TTM revenue decline erodes scale benefits and undermines margin realization. For a small consumer-health operator, falling sales strain distributor relationships, reduce bargaining power with retailers, and make it harder to absorb fixed costs, harming durable profitability prospects.
Negative Operating And Free Cash Flow (~-$0.3M TTM)Persistent negative OCF and FCF means the business is not yet self-funding and must rely on external financing. That constrains reinvestment in marketing, R&D, or distribution and raises capital risk if revenue weakness continues, threatening medium-term sustainability.
Rising Leverage And Contracting Equity BaseAn increase in debt-to-equity and a shrinking equity base reduce financial flexibility. Higher leverage elevates interest and refinancing risk, limiting the company's ability to withstand continued revenue pressure and increasing the likelihood of dilutive or costly financing options.
Delivra Health Brands News
DHB FAQ
What was Delivra Health Brands’s price range in the past 12 months?
Delivra Health Brands lowest stock price was C$0.09 and its highest was C$0.37 in the past 12 months.
What is Delivra Health Brands’s market cap?
Delivra Health Brands’s market cap is C$3.44M.
When is Delivra Health Brands’s upcoming earnings report date?
Delivra Health Brands’s upcoming earnings report date is Oct 23, 2026 which is in 81 days.
How were Delivra Health Brands’s earnings last quarter?
Delivra Health Brands released its earnings results on May 29, 2026. The company reported -C$0.03 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.03.
Is Delivra Health Brands overvalued?
According to Wall Street analysts Delivra Health Brands’s price is currently Undervalued.
Does Delivra Health Brands pay dividends?
Delivra Health Brands does not currently pay dividends.
What is Delivra Health Brands’s EPS estimate?
Delivra Health Brands’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Delivra Health Brands have?
Delivra Health Brands has 31,261,782 shares outstanding.
What happened to Delivra Health Brands’s price movement after its last earnings report?
Delivra Health Brands reported an EPS of -C$0.03 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Delivra Health Brands?
Currently, no hedge funds are holding shares in TSE:DHB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Delivra Health Brands
Based in Vancouver, Canada, Delivra Health Brands Inc., through its various subsidiaries, distributes an assortment of lifestyle and wellness goods to a global clientele of consumers and medical patients within regulated jurisdictions. The firm's product line includes cannabis, liquid sleep supplements, powdered sleep aids, edible gummies, and topical pain relief solutions. These items are available under well-known brand labels like LivRelief, Dream Water, and LivRelief Infused. The company was formerly recognized as Harvest One Cannabis Inc.
DHB Stock 12 Month Forecast
Average Price Target
C$0.53
▲(430.00% Upside)